Dr Krishna Ella, President and MD, Bharat Biotech, said that data analysis is underway for the world’s first nasal COVID vaccine.
Bharat Biotech completes clinical trials for the world’s first nasal COVID vaccine. (image for representation: AFP)
Dr Krishna Ella, President and MD, Bharat Biotech said that they have completed a clinical trial for the world’s first clinically proven nasal COVID-19 vaccine. “The data analysis is underway. We will submit the data to the regulatory agency. If all goes well, we will get permission to launch and this will be the world’s first clinically proven nasal COVID-19 vaccine,” said Dr. Krishna Ella was quoted as saying by ANI.
The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has given ‘in-principle’ approval to Bharat Biotech for a ‘Phase-III Booster Dose Study’ for its Intranasal COVID Vaccine, the first of its kind in India. Is. And asked it to submit the protocol for approval a few weeks back.
look | Bharat Biotech seeks approval for intranasal covid-19 vaccine as a booster dose
According to the Bharat Biotech website, “An intranasal vaccine stimulates a broad immune response involving neutralizing IgG, mucosal IgA, and T cell responses and creates an immune response at the site of infection (in the nasal mucosa) that triggers infection.” And it is necessary to block both the transmission of covid. -19.”
Bharat Biotech is the second company to submit applications for Phase III trials of the third dose in India. Intranasal vaccines reportedly have the ability to prevent the transmission of newer COVID-19 variants such as Omicron.
India has approved Covidshield, Covaxin and Sputnik V for vaccination in the country. Covaxin is approved for use under DCGI’s 28-day multiple-dose vial policy (MDVP) and the WHO Emergency Use List (WHO EUL).